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Introduction: An epidemiological study was conducted of a perfluorononanoic acid (PFNA) surfactant blend,
to investigate whether clinical differences were apparent between employees who were potentially exposed to
the surfactant and those who were not exposed. The surfactant blend, which is related to other previously
studied perfluorinated materials, is used in the production of some high-performance polymers.
Methods: All 630 individuals employed at a polymer production facility using PFNA (CAS No 72968-38-8)
at any time between 1 January 1989 and 1 July 2003 were included in the cohort. Plausibly related
laboratory test results were abstracted from annual medical examination records, including liver enzyme
function and blood lipids. Detailed work histories, available for all employees, provided the basis for
determining exposure category. Thirty two clinical parameters were evaluated by exposure level at five points
in time, determined to reflect changes in possible exposure intensity, as well as greatest number of records
available. Annual cross-sectional analyses and longitudinal analyses that accounted for multiple
measurements per person were conducted separately for men and women, by exposure groups.
Results: Differences by exposure group for all laboratory measures, adjusted for age and body mass index,
were small and not clinically significant. Although some statistically significant pair-wise differences were
observed, these observations were not consistent between men and women, or over the five analysis
windows. For the seven outcome variables (liver enzymes and blood lipids) examined in separate longitudinal
models, no significant increase or decrease was observed by unit increase in cumulative exposure intensity
score.
Conclusion: This is the first epidemiological study investigating the possible health effects in humans
associated with exposure to PFNA blend. Based on laboratory measures assessed over more than a decade,
no adverse clinical effects were detected from occupational exposure to PFNA blend.
F
or more than a decade, the public health relevance of
exposure to perfluorooctanoic acid (PFOA or C8) has been
examined because of its biological persistence and the lack
of information on possible long-term health implications. PFOA
has been detected in blood bank samples across the US as well
as in individuals across the globe (World Wildlife Fund, 2004).1
A related long-chain fluorinated hydrocarbon, perfluoronona-
noic acid (PFNA or C9), is the principal carbon chain-length in
a surfactant or ‘‘slip-agent’’ blend (CAS No 72968-38-8) used in
the production of some high-performance polymers. The
remaining fluorinated hydrocarbons in the blend consist
primarily of C11 and C13 congeners. Because the perfluorinated
compounds in the blend may also persist biologically, manage-
ment of a chemical production facility using this blend was
interested in whether measurable health effects were associated
with employee exposures. A limited number of toxicological
studies have been conducted by the manufacturers and users of
PFNA, and no epidemiological studies have been published to
date. Therefore, the limited toxicological data on PFNA and the
epidemiological findings regarding the related compound,
PFOA, served to frame the research questions.
A 90-day rat PFNA feeding study with a 60-day recovery
period suggested that the liver was the main target organ, with
effects on serum clinical chemistry, higher liver weights, and
evidence of peroxisome proliferation in both males and females.
Microscopic lesions in the liver and gastrointestinal tract were
noted in the male rats. At the end of the recovery period most of
the affected parameters had partially or completely returned to
normal. The enhanced effect in the males was consistent with
the observed higher serum levels of the surfactant (WIL
Research Laboratories, LLC. Study number WIL-497002,
2006). Similarly, toxicity studies of PFOA in animals have
shown effects on lipid metabolism (for example, reduction of
serum cholesterol) and changes in liver function (for example,
hepatic enzyme tests).2
The epidemiological investigations conducted at plant sites
where PFOA is either manufactured or used in polymer
production provided additional guidance for relevant clinical
hypotheses. Two studies that evaluated possible liver effects
associated with PFOA exposure in a polymer production area
found no impairment of liver function based on blood liver
function tests (DuPont, 1981, 1983). Similarly, studies of 3M
employees found no excess of liver cancer deaths attributable to
PFOA (University of Minnesota School of Public Health,
2001),3 4 and no changes in liver function parameters were
observed.5 A more extensive study of serum concentration of
perfluorooctanesulfonate (PFOS), another C8 fluorocarbon
compound, found no association with changes in blood clinical
chemistries or haematology after adjusting for other clinical
measures, such as age and lifestyle factors.6 This study was
consistent with studies of PFOA exposures, finding no adverse
changes in blood chemistries (that is, markers of disease) or
increases in cancer mortality.
Based on the positive findings for liver and blood lipid
changes in rats exposed to PFNA blend, and the choice of blood
chemistry tests evaluated in the epidemiological studies of a
similar compound, PFOA, the current study evaluated a
number of clinical laboratory measurements collected over a
period of more than 25 years among employees of a US
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production facility using the PFNA blend. The facility, which
manufactures a variety of chemicals and polymers, is located in
a rural area, and employees typically reside in communities
near the plant. The study was designed to identify whether any
differences in clinical measures could be identified between
employees in surfactant-exposed jobs compared to employees
in non-exposed jobs.
METHODS
All individuals ever employed at the facility at any time
between 1 January 1989 and 1 July 2003 were eligible to be
included in the study cohort. This start date was selected
because medical data were known to be complete beginning in
1989, and computerisation of existing employment records
began in the early 1990s. The study protocol was reviewed by a
federally (US) registered institutional review board.
Complete work history, date of birth, gender and race were
available for all individuals actively employed at the facility for
at least one day between 1 January 1989 and 1 July 2003.
Employment data were available since the plant opened in
1949, allowing complete reconstruction of employment his-
tories for all cohort members hired before the study start date.
Starting in 1989, annual medical examinations were con-
ducted, generally around the anniversary of an employee’s date
of hire, and nearly all medical records were located. Exams
were also provided at entry, retirement and to those re-hired
after lay-off. Many employees had medical records generated
before 1989—some going back to 1957—but these early records
were not uniformly available or complete. There is no
documented rationale or systematic pattern identified to
explain missing records prior to 1989.
Records were abstracted for height, weight, date of exam,
and 32 clinical chemistry variables (calcium, phosphorus,
sodium, potassium, chloride, alkaline phosphatase, total
protein, albumin, globulin, creatinine, glucose, iron; A/G ratio,
BUN, BUN/creatinine LDH, AST, ALT, GGT, total bilirubin, total
cholesterol, triglycerides, HDL cholesterol, LDL cholesterol,
VLDL cholesterol, total cholesterol/HDL ratio, LDL/HDL ratio,
TSH, thyroxine (T4), T3 uptake, free thyroxine index, uric
acid). Three laboratories had been used by the company since
1989, and a fourth lab was used from 1976–88. We used the
reference ranges from the laboratory used for the greatest
number of years, which was also the most recent laboratory
used by the plant, to identify values that could be considered
abnormal.
Complete work histories were available for all employees.
Each job record provided: date of hire into the company, job
title, start date for specific job, job and location codes. Working
with plant staff, all job titles were reviewed to identify those
with potential surfactant exposure, and to consolidate multiple
job titles that occurred for the same job over time. Employees
with jobs in maintenance or technical positions were consid-
ered exposed to surfactant, though at a lower level than the
process workers and other workers in the building manufactur-
ing the polymer. A non-exposed group consisted of adminis-
trative jobs and jobs in various other production processes at
the facility that did not use the PFNA blend and worked in
different buildings at the plant site. The final classification
consisted of three exposure categories: high exposure (process
job titles); low exposure (finishing, supervisory, lab, clerk,
maintenance, and technical job titles); and no exposure (other
processes, administrative job titles).
A variable representing the highest exposure level achieved
by a worker was created using the final three surfactant
exposure categories. Assignment to the exposure categories was
hierarchical and mutually exclusive at any particular point in
time. That is, once an employee was in a ‘‘high’’ exposure
process job, his or her exposure was considered ‘‘high’’ for that
year, and subsequent years. It is possible for an employee
assigned to ‘‘low’’ or ‘‘no exposure’’ to move to a higher
exposure group over time in the analysis, but not the reverse.
Before the start of the epidemiological study, the company
had obtained blood samples from a subset of current employees
who worked in various areas of the plant, to ascertain whether
PFNA levels could be detected in the blood. These limited
biomonitoring results were used to validate the exposure
categories generated based on the occupational history, but
were insufficient to be used in any analyses.
Three main analyses were conducted. First, a cross-sectional
analysis was conducted to evaluate differences in average
values of all 32 clinical laboratory measures at five points in
time. Additional annual cross-sectional analyses of mean lab
values by exposure groups and longitudinal analysis accounting
for multiple measurements per person were also conducted.
Analyses used the three exposure groups for men and two
groups for women, combining ‘‘high’’ and ‘‘low’’ because few
women worked in the process area historically. All analyses
were adjusted for age and body mass index (BMI), used as
continuous variables. All analyses were conducted in SAS 8.0
(SAS Institute, Cary, NC, USA).
Five time periods were selected for cross-sectional analysis
based on the following: (a) the earliest year (1976) sufficient
clinical chemistry data were available for analysis; (b) the year
(1989) complete medical records became available from the
facility; (c) the year (1995) a liquid solution started to replace
the powder form of surfactant; (d) the year (1998) following
complete conversion of surfactant from powder to solution; (e)
the latest year (2001) with sufficient data for analysis. Each
time period, or analysis ‘‘window’’ encompassed a two-year
period around the five key dates in order to capture the annual
physical examination for each employee, and to reflect different
exposure potential. For example, the 1989 period is believed to
be indicative of the entire period when powdered surfactant
blend (with potential for airborne dust exposure) was used,
whereas the 1995 period would reflect lower potential airborne
dust exposures. Many employees contribute data in multiple
analysis windows. Laboratory test results dated closest to the
mid-point of each analysis window were evaluated by exposure
groups. Pairwise comparisons of adjusted means of each lab
test were made across exposure groups in each analysis window
using PROC GLM in SAS.
Based on findings in rats that liver enzymes and blood lipids
may be the most likely to show any effects from exposure,
adjusted annual means for these tests results by exposure group
were graphed separately for men and women, using all years
with data available. As with the analysis windows, each
consecutive year does not represent the exact same group of
individuals, because of the dynamic workforce, with substantial
overlap from year to year.
Data used in the longitudinal analysis included annual
measures of liver enzymes and blood lipids, age at entry into
the cohort, annual measures of BMI, a weighted cumulative
intensity score (up to the month before the annual exam) and
the exposure group (none or any) in the month before the
annual exam. A variable reflecting cumulative exposure to
surfactant was also created. Each subject was assigned an
annual weighted cumulative intensity score, where exposure
intensity was quantified as 0 while not exposed, 1 during low
exposure, and 2 during high exposure. Weighting was based on
the proportion of each year spent in each exposure category. In
addition, an indicator variable was created for powder or liquid
surfactant use at the time of the annual exam. The general
approach to the modelling was a mixed or random effects
model. All longitudinal analyses used PROC MIXED in SAS.
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RESULTS
As of 1 July 2003, a total of 269 men and women were actively
employed at the facility. An additional 361 former employees,
primarily retirees, were identified as having left the facility
between 1 January 1989 and 30 June 2003. Medical and
laboratory reports could not be located for 15 (2%) of the 630
eligible employees. Nineteen individuals with only one annual
physical examination and employed less than one month were
excluded, as well as one person who retired before 1989. For
three individuals, gender could not be determined from the
records or first name, leaving 518 men and 74 women with
sufficient data for analysis. Descriptive results stratified by the
five cross-sectional analysis windows are presented in table 1.
Means for all 32 laboratory measures were compared
pairwise among high, low and no exposure groups for each of
the five analysis windows; a linear trend test of means was also
calculated for each lab measure for men. Adjusted group means
for liver enzymes and blood lipids among men, as available, are
presented in table 2; results for women are in table 3. The few
statistically significant differences are noted in the table.
Overall, differences among exposure groups for all lab tests
were small, and not clinically significant. Although some
statistically significant pairwise comparisons were observed,
these observations were not consistent between men and
women, or over the five analysis windows.
In the extended cross-sectional analysis for men and women,
adjusted mean values of liver enzyme and blood lipid tests for
each exposure group were plotted by year, from 1976 through
2003. Only years having at least five individuals with a
particular laboratory test result were plotted. Values tended to
fluctuate slightly across exposure groups over the years; no
group mean was consistently elevated or depressed over the
years available. For some lab measures, dips and peaks over
time were observed; however, these shifts appeared to coincide
with changes in laboratories used to test the blood.
Table 4 provides a selection of results from the longitudinal
analysis for cholesterol and triglycerides. Too few data were
available for stable models using data from the women only.
The best fitting models included a variable for age, time, and
BMI, as well as cumulative exposure intensity score, exposure
status for a given year, and form of surfactant in use at the time
of medical exam. BMI was strongly correlated with blood lipid
levels in particular, and in the longitudinal analysis both BMI
and age were independent predictors of each of the outcomes
evaluated. For the seven outcome variables examined in
separate models (total cholesterol, GGT, AST, ALT, alkaline
phosphatase, bilirubin, triglycerides), no significant increase or
decrease was observed by unit increase in exposure intensity
score. The statistical interaction of ‘‘current exposure’’ and
surfactant form (powder vs liquid) was statistically significant
for some lab values; however, the direction of the association in
these instances was opposite that hypothesised.
DISCUSSION
This is the first epidemiological study to investigate the possible
association between exposure to PFNA surfactant blend and
routine clinical laboratory results. As with previous studies of
individuals occupationally exposed to a related compound,
PFOA,5–7 no clear impacts on clinical chemistry values were
found. In the current study, all individuals who had worked in
the facility at some time between 1989 and 2003 were included
in the study, eliminating any possible selection bias associated
with voluntary participation. Additionally, the stability of the
cohort (based on low employee turnover and longevity of
employment), and the large database of annual examinations
provided by the company, allowed for nearly complete annual
clinical and laboratory data. Some cohort members had more
than 20 annual medical exams while employed at the facility.
This considerable database provided sufficient data to allow us
to conduct reasonably powerful longitudinal analyses capable
of detecting small true differences.
Our analyses included a larger number of employees with
multiple years of laboratory measures (78% of 518 men in
the study cohort) than any previously published study of
Table 1 Descriptive characteristics of cohort at each of five cross-sections in time
1976, n (%*) 1989, n (%*) 1995, n (%*) 1998, n (%*) 2001, n (%*)
Gender
Men 163 (96) 289 (89) 323 (86) 289 (86) 261 (85)
Women 6 (4) 35 (11) 52 (14) 47 (14) 45 (15)
Race/ethnicity
White 144 (97) 284 (94) 346 (92) 308 (92) 277 (91)
Black 3 (2) 17 (6) 26 (7) 25 (7) 28 (9)
Other 1 (1) 2 (,1) 3 (1) 3 (1) 1 (,1)
Exposure category
Surfactant-high 14 (8) 35 (11) 34 (9) 35 (10) 30 (10)
Surfactant-low 104 (62) 206 (64) 259 (69) 234 (70) 224 (73)
No surfactant 51 (30) 83 (26) 82 (22) 67 (20) 52 (17)
Exposure category Mean Mean Mean Mean Mean
Men
Age High 40.4 51.0 53.9 53.2 51.6
Low 38.3 47.2 47.4 47.8 47.0
None 40.2 47.8 47.8 48.4 47.6
BMI High 25.0 26.3 27.3 27.8 28.8
Low 25.6 26.9 28.1 28.1 29.2
None 25.7 27.2 29.4 29.7 30.4
Years employed High 14.6 24.8 27.8 27.4 25.0
Low 11.7 19.9 18.8 18.8 17.0
None 12.7 20.2 19.2 18.3 17.7
Women
Age Exposed – 34.6 37.8 42.2 42.6
None – 41.8 45.4 47.0 48.1
BMI Exposed – 27.0 26.9 27.9 27.9
None – 24.9 26.8 28.2 28.4
Years employed Exposed – 8.1 9.1 13.0 12.3
None – 11.7 11.4 12.9 13.4
*May not add to 100% due to rounding.
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Table 2 Comparison of adjusted mean lab values (liver enzymes, blood lipids) across
exposure groups in men, 1976, 1989, 1995, 1998 and 2001
Laboratory measure Exposure level
Cross-sectional year*
1976 1989 1995 1998 2001
LDH High 177.7 145.7 156.1 149.2 165.0
Low 179.7 148.4 159.2 151.1 164.9
None 187.3 148.4 157.9 151.7 160.9
AST High 32.2 27.0 23.4 23.5 33.5
Low 30.5 29.1 23.9 22.5 27.2
None 31.5 27.6 22.8 21.5 24.3
ALT High 45.9 29.8 21.4 26.0 37.6
Low 38.0 34.1 24.4 25.8 33.1
None 40.0 33.6 22.8 24.9 28.2
Bilirubin High 0.58 0.52 0.59 0.67 0.62
Low 0.57 0.51 0.69 0.74 0.61
None 0.59 0.52 0.68 0.66 0.57
GGT High 20.0 23.5 38.5 42.3 41.6
Low 15.3 25.5 34.8 37.6 39.2
None 20.9 30.0 37.6 33.8 35.7
Alkaline phosphatase High 26.1 101.5 94.0 82.0 99.4
Low 28.1 100.1 88.6 76.9 95.2
None 29.1 97.0 86.6 72.1 91.2
Cholesterol (total) High 239.8** 241.4** 215.6 221.9 211.9
Low 207.7 211.7 203.3 205.4 202.9
None 227.8 227.1 206.7 209.5 199.7
Triglycerides High 231.9 204.2 204.7 202.3 175.1
Low 195.6 168.9 167.7 183.1 182.0
None 197.2 174.3 164.2 177.9 172.3
HDL High NA 51.5 37.2 44.6 44.3
Low NA 50.1 38.1 42.6 41.9
None NA 49.8 37.5 43.0 42.6
LDL High NA 147.0 142.9 142.2 134.7
Low NA 130.8 134.0 130.8 127.0
None NA 137.7 138.5 135.8 122.3
VLDL High NA NA 30.4 34.1 29.1
Low NA NA 26.7 30.6 30.9
None NA NA 28.9 30.7 34.1
NA, not complete for early years.
*Number per exposure group (H, high; L, low; N, none): 1976 (14 H, 104 L, 45 N); 1989 (33 H, 198 L, 58 N); 1995 (30
H, 239 L, 54 N); 1998 (29 H, 220 L, 40 N); 2001 (23 H, 208 L, 30 N).
**Significance of group mean differences adjusted for age and body mass index is p,0.05.
Pairwise differences between high and low; pairwise differences between low and none; pairwise differences
between high and none.
Table 3 Comparison of adjusted mean lab values (liver enzymes, blood lipids) for women in
exposed and unexposed groups, 1989, 1995, 1998 and 2001
Laboratory measure Exposed
Cross-sectional year*
1989 1995 1998 2001
LDH Yes 148.7 151.5 144.8 160.0
No 148.1 162.4 149.4 182.8
AST Yes 28.1 18.8 17.9 22.2
No 24.8 20.1 18.2 21.0
ALT Yes 30.1 14.4 15.9 20.4
No 27.0 15.3 15.9 20.3
Bilirubin Yes 0.37 0.51 0.57 0.43
No 0.37 0.55 0.56 0.47
GGT Yes 21.9 21.4 21.9 21.8
No 12.6 54.6 32.8 35.0
Alkaline phosphatase Yes 89.8 70.6 66.2 82.1
No 76.7 74.9 68.9 92.4
Cholesterol (total) Yes 182.5 177.3 197.4 203.4
No 194.7 217.3 225.7 220.7
Triglycerides Yes 81.1 103.2 112.3 111.5
No 87.5 158.6 149.0 165.9
HDL Yes 61.4 46.8 52.8 59.0
No 63.8 52.4 59.7 56.3
LDL Yes 91.3 109.5 122.1 121.6
No 118.7 130.8 133.0 131.5
VLDL Yes NA 20.5 22.4 22.0
No NA 20.2 21.9 29.2
NA, not complete for early years.
*Number per exposure group (Y, exposed; N, not exposed): 1989 (10 Y, 25 N); 1995 (24 Y, 28 N); 1998 (20 Y, 27 N);
2001 (23 Y, 22 N).
Group mean differences adjusted for age and body mass index. No comparisons were significant at the p,0.05 level.
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occupational exposure to perfluorinated compounds. The long-
itudinal modelling was a powerful analysis that included
parameters to account for: (1) randomness in the outcome
due to the subject measured; and (2) correlation between
measurements made on the same subject. This analysis was
sufficiently robust to detect small changes in lab means
between exposure groups, as indicated by the precision in the
interval estimates.
Studies of rats exposed to PFOA, a related fluorinated
hydrocarbon compound, have indicated the liver may be a key
target organ for toxicity, as well as lipid metabolism as a response
indicator.2 Weight loss (wasting) has also been reported in rats.
Similar toxicity and wasting results in rats exposed to PFNA have
also been reported (WIL Research Laboratories, 2006). The
toxicokinetics of PFNA are currently unknown. Because no
studies of PFNA exposure in humans have been published,
studies of PFOA and PFNA effects in animals provided the basis
for hypothesising effects on liver enzymes and blood lipids. If the
rat data were indicative of possible human toxicity, the expected
findings for the current study would include elevated liver
enzymes among the exposed employees, as well as decreased
cholesterol and triglycerides. Such results were not found in this
study for either men or women.
In humans, several factors other than occupational chemical
exposure are likely to impact liver enzymes or blood lipids,
including age, medications, dietary supplements, existing
disease, weight, family history and alcohol abuse. Potential
confounding factors are unknown, as such factors would, by
definition, be risk factors for liver enzyme or blood lipid
changes that are also correlated with PFNA exposure. Our
analyses controlled for age and BMI; data were inconsistently
available for other exposures. Although information on alcohol
use was not available, we examined the ratio of AST/ALT
(aspartate transaminase, alanine transaminase) for values
greater than 1.5, as an indicator of possible alcohol-related
liver disease. Results of this analysis were negative.
Anecdotally, alcohol use in this population is believed to be
very low and infrequent—due to prevailing religious beliefs in
the plant community. Alcohol is not sold in the community in
which the facility is located or in several surrounding
communities, which also is likely to contribute to lower use.
Further, regular random drug and alcohol testing conducted at
the facility may deter alcohol abuse. Tobacco use was not
obtained for all individuals, however, it is unlikely that use
would affect liver enzymes or blood lipids.
Although different laboratories were used by the company
over the course of the study period, we do not consider this to
be a serious limitation. For the cross-sectional analyses we were
interested in the differences among the groups at a given point
in time, and any variation introduced by various labs used over
time would not matter. For any given year, all employee blood
drawn for testing was sent to the same lab. The longitudinal
analysis used values from different labs over time, and for the
earliest years of analysis some additional variability may have
been introduced. However, given that all blood values for a
given year were reported from a single lab, the relative position
of individuals, including by exposure category, would have
been preserved.
Extreme values for any of the 32 clinical tests were examined
at the individual level by a senior occupational physician, who
was blind to exposure status. Initially, extreme values were
defined as those outside the reference range of values as
specified in the most recent laboratory reports (LabCorp 2002).
For any extreme test results, the full medical record for these
individuals was reviewed. In each instance, valid medical
explanations for the extreme values were obtained from the
record. In no instance could extreme values be attributed to
high levels of exposure.
Based on rat studies, changes would be expected to occur in
blood chemistries from long-term PFNA exposure. However, it
is unknown in humans whether any potential changes in blood
chemistries due to PFNA exposure would occur immediately
upon exposure, after some lag period, or would require the
exceeding of some threshold of cumulative exposure. We
hypothesised that an effect, if one existed, would be during
the time period when the surfactant was used in powder form.
Before converting to a liquid suspension, those working in the
process area would have had the highest potential for exposure,
as the surfactant was manually measured and added to the
process. With transition to the liquid form, exposure to the
surfactant was more controlled. However, annual cross-
sectional analyses of all 32 laboratory measures by exposure
group showed no impact on blood chemistries before or after
conversion. Additionally, our longitudinal analyses, with up to
14 years of data for some individuals, are very robust for
detecting small changes in clinical chemistry values.
Longitudinal analyses, limited to the lipid profile and liver
enzymes, showed that cholesterol values were lower when the
powdered form of PFNA blend was used, but that cholesterol
values increased when PFNA was used as suspension. This
could be consistent with the interpretation that, as in rats,
exposure reduced cholesterol levels. However, given likely very
low PFNA exposures when used as suspension, no effect on
cholesterol would be expected and the observed non-significant
increasing cholesterol trend may be a coincidence or attribu-
table to unmeasured variable differences in the group.
PFNA surfactant blend is used, to our knowledge, in two
locations in the US, one of which is owned by the sponsor of the
study. Given the reasonably large sample size of this study, the
negative results most likely represent a null effect of exposure.
Additionally, the robustness of the repeated measures long-
itudinal analysis allowed for examination of clinical results by
individuals over many consecutive years. In summary, this
study, based on several clinical measures assessed over more
Table 4 Estimated effects of surfactant exposure on total cholesterol and triglycerides*
Effect Change in total cholesterol Standard error (95% CI)
1 unit change in cumulative exposure
intensity score
–0.257 0.135 (–0.521 to 0.006)
Current exposure, by operating condition:
Powder –2.0109 1.5587 (–5.066 to 1.044)
Non-powder 1.4807 1.6898 (–1.831 to 4.793)
Effect Change in triglycerides Standard error (95% CI)
1 unit change in cumulative exposure
intensity score
–1.054 0.5813 (–2.193 to 0.085)
Current exposure, by operating condition:
Powder 4.1465 6.935 (–9.446 to 17.739)
Non-powder 16.0581 7.4959 (1.366 to 30.750)
*Estimates adjusted for time, age, and body mass index.
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than a decade, has detected no adverse clinical effects from
occupational exposure to PFNA.
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Main messages
N Little is known about the human health effects, if any, of
various perfluorinated hydrocarbons. Much attention has
focused on perfluorooctanoic acid (PFOA), based on an
8-carbon chain, but no epidemiological data are
available on perfluorononanoic acid (PFNA), a 9-carbon
compound.
N In an occupational epidemiological study of 630 workers
potentially exposed to a PFNA blend, no meaningful
differences were observed for any of 32 clinical
laboratory measures, including liver enzymes and blood
lipids, between employees more likely highly exposed
and those believed to be unexposed to PFNA.
N Longitudinal analyses, using repeated measures of
clinical outcomes, and controlling for age, body mass
index and time period did not modify findings of no
differences in blood lipids or liver enzymes.
Policy implications
N This is the first epidemiological study of employees
occupationally exposed to PFNA, and with respect to
liver enzymes and blood lipids no clinically meaningful
differences were observed by category of exposure to
PFNA.
N Our negative findings are consistent with the lack of
association found in similar studies conducted among
employees exposed to other fluorinated hydrocarbons,
specifically PFOA, in other industries.
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